Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

2008 ◽  
Vol 35 (10) ◽  
pp. 1847-1856 ◽  
Author(s):  
Lisa Bodei ◽  
Marta Cremonesi ◽  
Mahila Ferrari ◽  
Monica Pacifici ◽  
Chiara M. Grana ◽  
...  
Keyword(s):  
Risk Factors ◽  
Radionuclide Therapy ◽  
Renal Toxicity ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor ◽  
Term Evaluation ◽  
Associated Risk Factors

scholarly journals Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide

Theranostics ◽  
2012 ◽  
Vol 2 (5) ◽  
pp. 472-480 ◽  
Author(s):  
Ebrahim S. Delpassand ◽  
Amin Samarghandi ◽  
Jennifer Sims Mourtada ◽  
Sara Zamanian ◽  
Gregory D. Espenan ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Toxicity Profile ◽  
Term Survival ◽  
Peptide Receptor ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Pet Ct Scan

scholarly journals RADIONUCLIDE IMAGING AND THERAPY OF NEUROENDOCRINE TUMOURS

2015 ◽  
Vol 1 (2) ◽  
Author(s):  
Shaunak Navalkissoor ◽  
Gopinath Gnanasegaran
Keyword(s):  
Radionuclide Imaging ◽  
Radionuclide Therapy ◽  
Neuroendocrine Tumours ◽  
Somatostatin Receptor ◽  
Peptide Receptor Radionuclide Therapy ◽  
Clinical Results ◽  
It Use ◽  
Peptide Receptor ◽  
Mibg Therapy

The incidence and prevalence of neuroendocrine tumours (NETs) are on the rise. Although NETs are a heterogeneous group of tumours, they have some similar properties, for example, that they can concentrate neuroamines and tend to have a high degree of somatostatin receptor (SSR) expression. These mechanisms can be exploited and this article discusses the important role of radionculide imaging and radionculide therapy in the management of NETs based on these mechanisms. This article reviews the current literature and discusses the role of radionuclide imaging in NETs both in terms of SSR imaging and neuroamine (metaiodobenzylguanidine [MIBG]) imaging. We discuss state-of- the-art 68Ga-radiopeptide imaging and indications for it use. We also discuss the role of 18F-FDG and other tracers in the management of NETs. The second half of the article focuses on radiotargeted treatment of NETs, discussing I-131 MIBG therapy and focussing on the emergence of peptide receptor radionuclide therapy. We discuss the clinical results, toxicities and patient selection for PRRT. Key words: DOTA octreotide, DOTATATE, Ga-68, Lu-177, metaiodobenzylguanidine, neuroendocrine tumours, peptide receptor radionuclide therapy, Y-90 

Tu1923 Long-Term Survival Data in Progressing Advanced Midgut Neuroendocrine Tumours Following Peptide Receptor Radionuclide Therapy

2015 ◽  
Vol 148 (4) ◽  
pp. S-936
Author(s):  
Mehmet Yalchin ◽  
Amelia Oliveira ◽  
Deborah Pencharz ◽  
Shaunak Navalkissoor ◽  
Ann-Marie Quigley ◽  
...  
Keyword(s):  
Survival Data ◽  
Radionuclide Therapy ◽  
Neuroendocrine Tumours ◽  
Peptide Receptor Radionuclide Therapy ◽  
Term Survival ◽  
Long Term Survival ◽  
Peptide Receptor

The role of patient-based treatment planning in peptide receptor radionuclide therapy

2015 ◽  
Vol 43 (5) ◽  
pp. 871-880 ◽  
Author(s):  
Deni Hardiansyah ◽  
Christian Maass ◽  
Ali Asgar Attarwala ◽  
Berthold Müller ◽  
Peter Kletting ◽  
...  
Keyword(s):  
Treatment Planning ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor

The role of dosimetric calculations in optimizing peptide receptor radionuclide therapy by [177Lu-DOTA0, Tyr3] octreotate

2014 ◽  
Vol 30 ◽  
pp. e114-e115 ◽  
Author(s):  
Irini Baka ◽  
Maria Argyrou ◽  
Marina Michalitsi ◽  
Alexia Valassi ◽  
Agapi Ploussi ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor

scholarly journals Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate

2011 ◽  
Vol 52 (8) ◽  
pp. 1197-1203 ◽  
Author(s):  
S. Ezziddin ◽  
A. Sabet ◽  
F. Heinemann ◽  
C. J. Yong-Hing ◽  
H. Ahmadzadehfar ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor

Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate

2013 ◽  
Vol 41 (3) ◽  
pp. 505-510 ◽  
Author(s):  
Amir Sabet ◽  
Khaled Ezziddin ◽  
Ulrich-Frank Pape ◽  
Karl Reichman ◽  
Torjan Haslerud ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Accurate Assessment ◽  
Peptide Receptor
Sign in / Sign up

Export Citation Format

Share Document